Al Sandrock

Putting Bio­gen's Aduhelm cri­sis be­hind him, Al San­drock grabs CEO role at gene ther­a­py play­er to lead turn­around mis­sion

Al San­drock’s re-en­try back to biotech comes just as abrupt­ly as his last ex­it.

The Bio­gen vet — who re­tired last No­vem­ber as R&D chief af­ter steer­ing the Alzheimer’s drug ad­u­canum­ab (now Aduhelm) straight in­to a storm of con­tro­ver­sy sur­round­ing its ap­proval and roll­out — has tak­en Voy­ager Ther­a­peu­tics’ of­fer to be its CEO.

Voy­ager was San­drock’s first port of call af­ter he left Bio­gen. He joined not just the board but a new­ly formed three-per­son ex­ec­u­tive team tasked with guid­ing the gene ther­a­py com­pa­ny as it tries to re­brand it­self af­ter two trou­bled years. He’s since amassed a dozen of oth­er board seats.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.